Technology
5N Plus Inc. Reports Fourth Quarter and Fiscal Year 2024 Financial Results
Published
1 year agoon
By
19% growth in annual revenue to $289.3 million39% growth in annual Adjusted EBITDA1 to a record $53.3 millionAnnual Adjusted gross margin percentage1 of 31.6%Backlog1 of $252.8 million, representing 326 days of annualized revenue, as at December 31, 2024Increases 2025 Adjusted EBITDA guidance to a range of $55 to $60 million
MONTREAL, Feb. 25, 2025 /CNW/ – 5N Plus Inc. (TSX: VNP) (“5N+” or “the Company”), a leading global producer of specialty semiconductors and performance materials, today announced its financial results for the fourth quarter of fiscal 2024 (“Q4 2024”) and fiscal year (“FY 2024”) ended December 31, 2024. All amounts in this press release are expressed in U.S. dollars unless otherwise stated.
“We had an outstanding year in FY 2024, generating stellar financial and operational results. We generated record annual Adjusted EBITDA representing 39% growth over the previous year, delivered on our margin expansion efforts, and sustained an elevated backlog and a solid balance sheet. We also successfully increased capacity at several sites to meet demand in strategic sectors, with work underway to increase solar cell capacity at AZUR by an additional 30% this year, on top of the 35% achieved last year. Looking at our segments, in Specialty Semiconductors, we continued to benefit from our unique position as the leading supplier outside China and trusted partner in the growing terrestrial renewable energy and space solar power sectors. In Performance Materials, our improved product mix and solid operational execution also contributed to strong profitability,” said Gervais Jacques, President and CEO of 5N+.
“Our strategic focus on higher margin, value-added advanced materials and on being a critical supplier without being a critical cost to customers operating in growing markets continues to pay off. This is further supported by our recognition as a reliable partner and market leader with unique expertise and manufacturing capabilities. With our resilient and agile business model as our foundation, we will continue to leverage our strategic positioning and competitive advantages to build on our FY 2024 momentum as we enter 2025 and forge ahead on our profitable growth path,” concluded Mr. Jacques.
Financial Highlights
Revenue in Q4 2024 increased by 9% to $70.9 million, compared to $65.1 million in Q4 2023, driven by strong growth under Specialty Semiconductors. Revenue in FY 2024 reached $289.3 million, compared to $242.4 million in FY 2023, supported by the terrestrial renewable energy and space solar power sectors under Specialty Semiconductors.Adjusted EBITDA in Q4 2024 increased by 38% to $12.5 million, compared to $9.0 million in Q4 2023, driven by higher volume from the terrestrial renewable energy and space solar power sectors, and better prices over inflation. Adjusted EBITDA was $53.3 million in FY 2024, representing a 39% increase compared to $38.3 million in FY 2023.Adjusted gross margin1 increased by 26% to $23.4 million in Q4 2024, favourably impacted by the same factors as above. Adjusted gross margin as a percentage of sales was 33.0% in Q4 2024, compared to 28.5% in Q4 2023. Adjusted gross margin reached $91.3 million for FY 2024, or 31.6% of sales, compared to $70.2 million in FY 2023, or 29.0% of sales.Net earnings in Q4 2024 were $1.0 million, compared to $2.3 million in Q4 2023. For FY 2024, net earnings were $14.7 million, compared to $15.4 million in FY 2023.Backlog stood at $252.8 million, representing 326 days of annualized revenue as at December 31, 2024, 37 days higher than the previous quarter and 34 days higher than at the end of last year, primarily due to the timing of contract signings and renewals.Net debt1 was $100.1 million as at December 31, 2024, compared to $73.8 million as at December 31, 2023, reflecting an increase in working capital1 and planned capital expenditures in 2024 under Specialty Semiconductors. The Company’s net debt to EBITDA ratio1 stood at 2.02x as at December 31, 2024.
____________________________
1 These measures are not recognized measures under IFRS and do not have standardized meanings prescribed by IFRS and therefore may not be comparable to similar measures presented by other companies. See Non-IFRS Measures for more information.
Market Outlook
In Specialty Semiconductors, 5N+ continues to benefit from its unique position as the leading global supplier of ultra-high purity semiconductor compounds outside China, with long-term partnerships with key customers. Growing demand remains the rule, particularly in terrestrial renewable energy and space solar power. 5N+ is well-positioned to capitalize on future opportunities in these high-growth sectors.
The Company also anticipates growth under imaging and sensing applications including in the security, defence and medical sectors. The anticipated transition to photon counting detector (PCD) technology for medical imaging is anticipated to provide a promising growth avenue in the medium term.
Management expects growth in the Performance Materials segment to be primarily driven by the health and pharmaceutical sector, which provides high profitability and predictable cashflows. We expect demand for bismuth chemicals to continue to grow in line with GDP in respective markets.
As a result of increased production capacity and operational flexibility, 5N+ is in a position to efficiently capture additional organic growth opportunities in the near term, while it also actively pursues external growth opportunities.
Based on under-contract and anticipated near-term demand primarily driven by the Specialty Semiconductors segment, management anticipates generating Adjusted EBITDA in a range of $55 to $60 million in 2025, representing an upward revision of its previously disclosed range of $50 to $55 million.
The recent change in administration in the U.S. creates uncertainty in the global economic outlook, particularly regarding potential trade protectionist measures that could trigger retaliatory actions from affected countries. Given the rapidly evolving landscape and the potential impact of these measures, the Company has elected to defer providing guidance for 2026 until it has had the opportunity to further assess the direct and indirect impacts on its business and operations. The Company remains committed to its long-term objectives and the execution of its strategic initiatives.
The Company intends to leverage its strategic positioning and competitive advantages to build on its FY 2024 momentum as it enters 2025 and to navigate any potential headwinds that result from the evolving macro-economic and geopolitical environment.
Conference Call
5N+ will host a conference call on Wednesday, February 26, 2025, at 8:00 a.m. Eastern Time to discuss Q4 and FY 2024 financial results. All interested parties are invited to participate in the live broadcast on the Company’s website at www.5nplus.com.
To participate in the conference call:
Toronto area: 289-819-1299Toll‐Free: 1-800-990-4777Enter access code: 71321
A replay of the conference call will be available two hours after the event and until March 5, 2025. To access the recording, please dial 1-888-660-6345 and enter access code 71321.
________________________________
1 These measures are not recognized measures under IFRS and do not have standardized meanings prescribed by IFRS and therefore may not be comparable to similar measures presented by other companies. See Non-IFRS Measures for more information.
About 5N+
5N+ is a leading global producer of specialty semiconductors and performance materials. The Company’s ultra‐pure materials often form the core element of its customers’ products. These customers rely on 5N+’s products to enable performance and sustainability in their own products. 5N+ deploys a range of proprietary and proven technologies to develop and manufacture its products. The Company’s products enable various applications in several key industries, including renewable energy, security, space, pharmaceutical, medical imaging and industrial. Headquartered in Montréal, Quebec, 5N+ operates R&D, manufacturing and commercial centers in strategically located facilities around the world including Europe, North America and Asia.
Forward‐Looking Statements
Certain statements in this press release may be forward‐looking within the meaning of applicable securities laws. Such forward‐looking statements are based on a number of estimates and assumptions that the Company believes are reasonable when made, including that 5N+ will be able to retain and hire key personnel and maintain relationships with customers, suppliers and other business partners, that 5N+ will continue to operate its business in the normal course, that 5N+ will be able to implement its growth strategy, that 5N+ will be able to successfully and timely complete the realization of its backlog, that 5N+ will not suffer any supply chain challenges or any material disruption in the supply of raw materials on competitive terms, that 5N+ will be able to generate new sales, produce, deliver, and sell its expected product volumes at the expected prices and control its costs, as well as other factors believed to be appropriate and reasonable in the circumstances. However, there can be no assurance that such estimates and assumptions will prove to be correct. These statements are not guarantees of future performance and involve assumptions, risks and uncertainties that are difficult to predict and may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward‐looking statements. A description of the risks affecting the Company’s business and activities appears under the heading “Risk and Uncertainties” of the Company’s 2024 MD&A dated February 25, 2025, available on www.sedarplus.ca.
Forward‐looking statements can generally be identified by the use of terms such as “may”, “should”, “would”, “believe”, “expect”, the negative of these terms, variations of them or any similar terms. No assurance can be given that any events anticipated by the forward‐looking statements in this press release will transpire or occur, or if any of them do so, what benefits that 5N+ will derive therefrom. In particular, no assurance can be given as to the future financial performance of 5N+. The forward‐looking statements contained in this press release is made as of the date hereof and the Company has no obligation to publicly update such forward‐looking information to reflect new information, subsequent or otherwise, unless required by applicable securities laws. The reader is warned against placing undue reliance on these forward‐looking statements. Forward-looking statements are presented in this press release for the purpose of assisting investors and others in understanding certain key elements of the Company’s expected financial results, as well as the Company’s objectives, strategic priorities and outlook, and in obtaining a better understanding of the Company’s anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes.
5N PLUS INC.
CONSOLIDATED STATEMENTS OF EARNINGS
Years ended December 31
(in thousands of United States dollars, except per share information)
2024
2023
$
$
Revenue
289,281
242,371
Cost of sales
211,413
184,833
Selling, general and administrative expenses
34,026
29,410
Other expenses (income), net
11,614
756
257,053
214,999
Operating earnings
32,228
27,372
Financial expenses
Interest on long-term debt
8,210
8,262
Imputed interest and other interest expense
959
572
Foreign exchange gain
(549)
(136)
8,620
8,698
Earnings before income taxes
23,608
18,674
Income tax expense (recovery)
Current
6,945
6,674
Deferred
1,991
(3,399)
8,936
3,275
Net earnings
14,672
15,399
Basic earnings per share
0.17
0.17
Diluted earnings per share
0.16
0.17
Net earnings are completely attributable to equity holders of 5N+.
5N PLUS INC.
CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
(in thousands of United States dollars)
December 31
2024
December 31
2023
$
$
Assets
Current
Cash
22,142
34,706
Accounts receivable
42,172
33,437
Inventories
137,823
105,850
Income tax receivable
1,811
1,672
Derivative financial assets
6,978
591
Other current assets
6,469
5,707
Total current assets
217,395
181,963
Property, plant and equipment
85,995
84,600
Right-of-use assets
28,583
29,290
Intangible assets
22,929
29,304
Goodwill
10,665
11,825
Deferred tax assets
7,358
8,261
Other assets
3,982
4,959
Total non-current assets
159,512
168,239
Total assets
376,907
350,202
Liabilities
Current
Trade and accrued liabilities
42,116
37,024
Income tax payable
5,207
4,535
Current portion of deferred revenue
11,206
13,437
Current portion of lease liabilities
1,952
1,811
Current portion of long-term debt
–
25,000
Total current liabilities
60,481
81,807
Long-term debt
122,203
83,500
Deferred tax liabilities
5,737
5,284
Employee benefit plan obligations
12,624
13,393
Lease liabilities
27,450
28,328
Deferred revenue
8,688
5,629
Other liabilities
706
3,669
Total non-current liabilities
177,408
139,803
Total liabilities
237,889
221,610
Equity
139,018
128,592
Total liabilities and equity
376,907
350,202
Non‐IFRS Measures
EBITDA means net earnings (loss) before interest expenses, income tax expense (recovery), depreciation and amortization. 5N+ uses EBITDA because it believes it is a meaningful measure of the operating performance of its ongoing business, without the effects of certain expenses. The definition of this non-IFRS measure used by the Company may differ from that used by other companies.
EBITDA is reconciled to the most comparable IFRS measure:
(in thousands of U.S. dollars)
Q4 2024
Q4 2023
FY 2024
FY 2023
$
$
$
$
Net earnings
1,006
2,284
14,672
15,399
Interest on long-term debt, imputed interest and other interest expense
2,446
2,129
9,169
8,834
Income tax expense (recovery)
2,415
(734)
8,936
3,275
Depreciation and amortization
4,373
4,057
16,791
16,110
EBITDA
10,240
7,736
49,568
43,618
EBITDA margin is defined as EBITDA divided by revenues.
Adjusted EBITDA means operating earnings (loss) as defined before the effect of impairment of inventories, share-based compensation expense (recovery), loss (gain) on disposal of property, plant and equipment, loss (gain) on remeasurement of financial instrument, impairment (reversal of impairment) of non-current assets, litigation and restructuring costs (income), and depreciation and amortization. 5N+ uses Adjusted EBITDA because it believes it is a meaningful measure of the operating performance of its ongoing business without the effects of certain expenses. The definition of this non-IFRS measure used by the Company may differ from that used by other companies.
Adjusted EBITDA margin is defined as Adjusted EBITDA divided by revenues.
Adjusted EBITDA and Adjusted EBITDA margin are reconciled to the most comparable IFRS measure:
(in thousands of U.S. dollars)
Q4 2024
Q4 2023
FY 2024
FY 2023
$
$
$
$
Revenues
70,854
65,063
289,281
242,371
Operating expenses
(64,701)
(61,023)
(257,053)
(214,999)
Operating earnings
6,153
4,040
32,228
27,372
Share-based compensation expense
309
414
906
1,432
(Gain) loss on disposal of property, plant and equipment
–
–
(2,089)
1,051
Loss on remeasurement of financial instrument
1,000
–
1,000
–
(Reversal of impairment) impairment of non-current assets
(120)
64
2,706
672
Litigation and restructuring costs (income)
769
458
1,790
(8,314)
Depreciation and amortization
4,373
4,057
16,791
16,110
Adjusted EBITDA
12,484
9,033
53,332
38,323
Adjusted EBITDA margin
17.6 %
13.9 %
18.4 %
15.8 %
Adjusted gross margin is a measure used to monitor the sales contribution after paying cost of sales, excluding depreciation and inventory impairment charges. 5N+ also expressed this measure in percentage of revenues by dividing the adjusted gross margin value by the total revenue.
Adjusted gross margin is reconciled to the most comparable IFRS measure:
(in thousands of U.S. dollars)
Q4 2024
Q4 2023
FY 2024
FY 2023
$
$
$
$
Total revenue
70,854
65,063
289,281
242,371
Cost of sales
(51,104)
(49,677)
(211,413)
(184,833)
Gross margin
19,750
15,386
77,868
57,538
Depreciation included in cost of sales
3,643
3,189
13,445
12,656
Adjusted gross margin
23,393
18,575
91,313
70,194
Adjusted gross margin percentage
33.0 %
28.5 %
31.6 %
29.0 %
Backlog represents the expected orders the Company has received, but has not yet executed, and that are expected to translate into sales within the next twelve months, expressed in dollars and estimated in number of days not to exceed 365 days. Bookings represent orders received during the period considered, expressed in number of days, and calculated by adding revenues to the increase or decrease in backlog for the period considered, divided by annualized year revenues. 5N+ uses backlog to provide an indication of expected future revenues in days, and bookings to determine its ability to sustain and increase its revenues.
Net debt is calculated as total debt less cash. Any introduced IFRS 16 reporting measures in reference to lease liabilities are excluded from the calculation. 5N+ uses this measure as an indicator of its overall financial position.
The net debt to EBITDA ratio is defined as net debt divided by the trailing 12 months EBITDA.
Total debt and Net debt are reconciled to the most comparable IFRS measure:
(in thousands of U.S. dollars)
As at December 31, 2024
As at December 31, 2023
$
$
Bank indebtedness
–
–
Long-term debt including current portion
122,203
108,500
Lease liabilities including current portion
29,402
30,139
Subtotal Debt
151,605
138,639
Lease liabilities including current portion
(29,402)
(30,139)
Total Debt
122,203
108,500
Cash
(22,142)
(34,706)
Net Debt
100,061
73,794
Working capital is a measure of liquid assets that is calculated by taking current assets and subtracting current liabilities. Given that the Company is currently indebted, it uses it as an indicator of its financial efficiency and aims to maintain it at the lowest possible level.
Working capital ratio is calculated by dividing current assets by current liabilities.
Working capital is reconciled to the most comparable IFRS measure:
(in thousands of U.S. dollars)
As at December 31, 2024
As at December 31, 2023
$
$
Inventories
137,823
105,850
Other current assets excluding inventories
79,572
76,113
Current assets
217,395
181,963
Current liabilities
(60,481)
(81,807)
Working capital
156,914
100,156
Working capital ratio
3.59
2.22
SOURCE 5N Plus Inc.
You may like
Technology
HelloNation Article Highlights Sterile Compounding and Medication Safety With Insights From Compounding Pharmacist Expert Laura Temple
Published
35 minutes agoon
July 21, 2026By
The article explains how sterile compounded medications are prepared to reduce the risk of contamination and support safe, customized treatments.
AZLE, Texas, July 21, 2026 /PRNewswire/ — What does sterile compounding mean for medication safety? HelloNation has published an article explaining how sterile compounding helps pharmacies prepare highly specialized medications while adhering to strict contamination-prevention procedures.
The article features insights from Laura Temple, Compounding Pharmacist Expert and Owner of Laura’s Pharmacy in Azle, Texas. It explains that sterile compounding is a specialized process for preparing medications in carefully controlled environments designed to reduce the risk of contamination. Sterile compounded medications are often used for injections, eye drops, IV medications, and other therapies that require the highest levels of cleanliness and precision.
The HelloNation article explains that sterile compounded medications differ from commercially manufactured drugs because they are prepared individually for a patient’s unique medical needs. Physicians may prescribe compounded prescriptions when a patient requires a customized dosage, a combination medication, or a treatment not commercially available. Because these medications often bypass the body’s natural defenses, medication safety depends on strict preparation standards throughout the compounding process.
The article describes how pharmacies that provide sterile compounding rely on cleanroom environments equipped with filtered-air systems, specialized equipment, and contamination-prevention protocols. Pharmacists and technicians follow detailed gowning, sterilization, and handwashing procedures before handling medication ingredients. These measures are designed to support medication safety by limiting exposure to bacteria, particles, and other contaminants.
According to the article, environmental monitoring also plays a critical role in sterile compounding. Temperature control, air quality testing, and routine equipment inspections help maintain consistent preparation standards. The article notes that sterile compounded medications may undergo additional quality assurance checks before being dispensed to patients. These procedures help support both treatment effectiveness and patient safety.
The HelloNation article also explains that pharmacies performing sterile compounding are expected to follow USP guidelines established for sterile preparation. These USP guidelines outline requirements for cleanroom pharmacy operations, environmental testing, employee training, and quality assurance practices. The article emphasizes that maintaining compliance with USP guidelines helps reinforce contamination prevention and consistent preparation standards for compounded prescriptions.
Patients seeking sterile compounded medications may also look for pharmacies that participate in accreditation programs or are overseen by state boards. The article explains that these programs review safety procedures, documentation practices, and facility standards to help maintain medication safety. Regular environmental monitoring and staff competency evaluations are also identified as important safeguards in sterile compounding operations.
The article further explains that communication between pharmacists, healthcare providers, and patients remains an important part of safe compounded prescriptions. Compounding pharmacists review prescriptions carefully, confirm dosing instructions, and evaluate ingredient compatibility before preparation begins. This collaborative approach supports medication safety by reducing the risk of errors and ensuring treatments meet individual patient needs.
The article concludes that sterile compounding continues to play an important role in healthcare, particularly for patients requiring customized therapies that are unavailable through traditional manufacturing channels. Whether preparing IV medications, injectable therapies, or other sterile compounded medications, pharmacies rely on contamination prevention procedures and strict preparation standards to support patient care. The article notes that understanding how sterile compounding works can help patients feel more informed about the safety measures involved in preparing specialized medications.
What Sterile Compounding Means for Medication Safety features insights from Laura Temple, a compounding pharmacist expert at Laura’s Pharmacy in Azle, Texas, on HelloNation.
About HelloNation
HelloNation is America’s Good News Network, a premier media platform built on the idea that good news travels faster when real people tell real stories. Through its community-focused publications and innovative “edvertising” approach, HelloNation delivers content that informs, inspires, and spotlights the leaders making a meaningful impact in their communities.
View original content to download multimedia:https://www.prnewswire.com/news-releases/hellonation-article-highlights-sterile-compounding-and-medication-safety-with-insights-from-compounding-pharmacist-expert-laura-temple-302831275.html
SOURCE HelloNation
Technology
CIOs Forced to Rethink Manual Compliance Processes as Regulatory Complexity Rises, Says Info-Tech Research Group
Published
35 minutes agoon
July 21, 2026By
Regulatory demands are increasing in volume, complexity, and speed, leaving many organizations reliant on fragmented, manual approaches that slow response times and increase risk. New insights from Info-Tech Research Group show that organizations need to adopt more structured and scalable approaches to keep pace with regulatory change. The firm’s recently published blueprint, Build a Regulatory IT Response Engine, provides frameworks, tools, and step-by-step guidance to help organizations translate regulatory requirements into actionable IT controls and prioritized initiatives.
ARLINGTON, Va., July 21, 2026 /PRNewswire/ — Growing regulatory pressure across jurisdictions is forcing organizations to rethink how they interpret, prioritize, and execute compliance requirements. Many IT teams continue to operate with inconsistent processes and limited coordination, resulting in delayed initiatives and increased exposure to financial and reputational risk. Info-Tech’s blueprint, Build a Regulatory IT Response Engine, introduces a coordinated and repeatable approach to help IT leaders operationalize compliance and improve execution outcomes.
Info-Tech’s findings indicate that while organizations recognize the need for faster and more consistent regulatory response, they continue to face barriers such as fragmented interpretation of requirements, weak prioritization, and limited scalability. AI-enabled tools can help streamline analysis and accelerate response planning, but without a coordinated approach grounded in governance and human oversight, those benefits are difficult to realize.
“Regulatory response is becoming too complex to manage through disconnected, manual processes,” says Ahmad Jowhar, senior research analyst at Info-Tech Research Group. “IT leaders need a repeatable way to interpret requirements, prioritize action, and use AI to accelerate planning without losing the governance and oversight needed to execute effectively.”
Key Challenges IT Leaders Face in Regulatory Response
Despite ongoing investments in compliance, organizations continue to face systemic challenges that hinder effective execution. Info-Tech’s blueprint highlights several areas where IT and compliance leaders struggle most:
Fragmented and manual processes that slow regulatory interpretation and response.Inconsistent application of regulatory requirements across teams and jurisdictions.Poor prioritization of IT initiatives, leading to missed deadlines and duplicated effort.Limited scalability to manage increasing regulatory volume and complexity.Misalignment between compliance activities and broader business priorities.
Info-Tech’s Framework for Building a Regulatory IT Response Engine
To address these challenges, Info-Tech recommends a structured, AI-enabled approach that improves consistency, speed, and scalability. The firm’s Build a Regulatory IT Response Engine blueprint outlines the following key priorities for IT leaders:
Define the regulatory landscape: Establish organizational context, governance structures, and a centralized inventory of applicable regulations.Translate requirements into IT controls: Use AI-enabled analysis and structured assessments to convert regulatory obligations into actionable controls.Prioritize IT initiatives: Align initiatives based on cost, effort, impact, and regulatory timelines to reduce execution risk.Build and communicate a roadmap: Develop a clear, resource-aligned roadmap to guide execution and stakeholder alignment.Establish a repeatable process: Continuously monitor, adapt, and refine regulatory response capabilities to maintain compliance over time.
Organizations that adopt this structured approach can move from reactive compliance efforts to a more proactive and scalable model that shortens response timelines, reduces manual effort, and strengthens execution.
The firm’s Build a Regulatory IT Response Engine blueprint includes practical tools such as a Regulation Inventory Tool, a Regulatory Response IT Action Plan Tool, a Communication Deck Template, and a Compliance Program Framework. By applying these resources, IT leaders can standardize regulatory responses, improve prioritization, and help ensure compliance initiatives are executed on time and in alignment with business priorities.
For exclusive and timely commentary from Info-Tech’s experts, including Ahmad Jowhar, and access to the complete Build a Regulatory IT Response Engine blueprint, please contact pr@infotech.com.
About Info-Tech Research Group
Info-Tech Research Group is the “get things done” partner for over 30,000 IT, HR, and marketing leaders worldwide. The fastest growing research and advisory firm, Info-Tech enables leaders to make well-informed decisions and transform their organizations through AI, strategic foresight, step-by-step methodologies, practical tools, industry-leading advisory, and training programs. For nearly 30 years, tens of thousands of private and public organizations have trusted Info-Tech to lead their most important initiatives through periods of change and deliver outcomes that truly matter.
To learn more about Info-Tech’s HR research and advisory services, visit McLean & Company, and for data-driven software buying insights and vendor evaluations, visit the firm’s SoftwareReviews platform.
Media professionals can register for unrestricted access to research across IT, HR, and software and hundreds of industry analysts through the firm’s Media Insiders program. To gain access, contact pr@infotech.com.
For information about Info-Tech Research Group or to access the latest research, visit infotech.com and connect via LinkedIn and X.
View original content to download multimedia:https://www.prnewswire.com/news-releases/cios-forced-to-rethink-manual-compliance-processes-as-regulatory-complexity-rises-says-info-tech-research-group-302831286.html
SOURCE Info-Tech Research Group
Technology
Atomera to Announce Second Quarter 2026 Financial Results and Host Webinar on Tuesday, August 4, 2026
Published
35 minutes agoon
July 21, 2026By
LOS GATOS, Calif., July 21, 2026 /PRNewswire/ — Atomera Incorporated (NASDAQ: ATOM), a semiconductor materials and technology licensing company, announced today that it plans to release its second quarter 2026 financial results after the market closes on Tuesday, Aug. 4, 2026.
The company will host a live video Zoom webinar at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) on Tuesday, Aug. 4, 2026, to discuss the results. The live webinar can be accessed through Atomera’s investor relations website at https://ir.atomera.com. A replay of the webcast will be available for 12 months. To pre-register for the webinar, use the following link.
https://atomera.zoom.us/webinar/register/WN_OJFbTWe1SIyV69LLdDadCw
About Atomera
Atomera Incorporated is a semiconductor materials and technology licensing company focused on deploying its proprietary, silicon-proven technology into the semiconductor industry. Atomera has developed Mears Silicon Technology™ (MST®), which increases performance and power efficiency in semiconductor transistors. MST can be implemented using equipment already deployed in semiconductor manufacturing facilities and is complementary to other nano-scaling technologies already in the semiconductor industry roadmap. More information can be found at www.atomera.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/atomera-to-announce-second-quarter-2026-financial-results-and-host-webinar-on-tuesday-august-4-2026-302830602.html
SOURCE Atomera Incorporated
HelloNation Article Highlights Sterile Compounding and Medication Safety With Insights From Compounding Pharmacist Expert Laura Temple
CIOs Forced to Rethink Manual Compliance Processes as Regulatory Complexity Rises, Says Info-Tech Research Group
Atomera to Announce Second Quarter 2026 Financial Results and Host Webinar on Tuesday, August 4, 2026
Send Rakhi to UK swiftly with UK Gifts Portal
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
New Gooseneck Omni Antennas Offer Enhanced Signals in a Durable Package
Why You Should Build on #NEAR – Co-founder Illia Polosukhin at CV Labs
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
NEAR End of Year Town Hall 2021: The Open Web World, MetaBUILD 2 Hackathon and 2021 recap
Trending
-
Coin Market5 days agoBitcoin outlook improves amid 6% weekly gain: Can BTC bulls push higher?
-
Technology5 days agoTimed with the Canton Fair, Connexion ShenZhen 2026 Unveils Major Fourth-Edition Upgrades as a Greater Bay Area Mega Sourcing Event
-
Coin Market4 days agoThe British Virgin Islands are a top crypto hub no one ever talks about: Here’s why
-
Technology4 days agoGlobal Times: China sends fresh signal on global AI cooperation at WAIC
-
Coin Market5 days agoTrump teleprompter operator made $100K betting on Kalshi markets tied to speeches: ABC
-
Technology5 days agoGrand Bargain Project Announces Procedural Change that Will Turn Congress into a Problem-Solving Institution Within Days
-
Technology5 days agoDrake Expands End-to-End Professional Services with Launch of Drake Audit Defense™
-
Technology5 days agoTexas Instruments board declares third quarter 2026 quarterly dividend
